We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
Note: As a result of the current COVID-19 (Coronavirus) restrictions, research sites may incorrectly be listed as recruiting or be delayed in responding to patient inquiries due to possible closures. It is suggested that interested patients awaiting a response or current study patients can contact the research site at the phone number provided to ask about study status or confirm scheduled appointments before arriving. Read more about BMS's response to COVID-19 at www.BMS.com.
Gastrointestinal (GI) cancer is a term for the group of cancers that affect the digestive system. This includes cancers of the esophagus, gallbladder & biliary tract, liver, pancreas, stomach, small intestine, bowel (large intestine or colon and rectum), and anus.
Jump to Studies
Gastric, Esophageal and GEJ | Colorectal | Pancreatic | Liver
We have several clinical trials that are currently recruiting to evaluate experimental medications for gastrointestinal (GI) cancer. See if there are clinical trials that might be right for you.
Thank you for Considering a Clinical Trial
Below you will find clinical trials that are either currently recruiting patients (noted as Recruiting) or starting to recruit patients soon (noted as Not Yet Recruiting).
Here are some options for you to find more information:
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors
View Trial DetailsA Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
View Trial DetailsA Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors
View Trial DetailsA Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
View Trial DetailsA Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
View Trial DetailsA Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
View Trial DetailsGet updates on clinical trials
Esophageal cancer occurs when tumors form in the tissues of the esophagus, which is a muscular tube that moves food and liquids from the throat to the stomach for digestion.
Learn MoreHepatocellular Carcinoma (HCC) is the most common type of primary liver cancer
Learn MoreThe signs & symptoms of gastric cancer can vary depending on the stage of the cancer. In general, symptoms may also be associated with other conditions. Talk to your doctor if you have any of these symptoms.
Learn MoreColorectal cancer, or CRC, is a cancer that forms in the tissues of the colon or rectum, which are part of the body’s digestive or gastrointestinal (GI) system.
Learn MoreBristol Myers Squibb is not affiliated with nor endorses any of the listed organizations. The information/links provided by Bristol Myers Squibb are meant for informational purposes only and are not meant to replace a physician's medical advice or imply endorsement.
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information